71 results
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 May 24
Regeneron Reports First Quarter 2024 Financial and Operating Results
7:06am
and Chief Financial Officer of Regeneron. "While investing in innovation remains our top capital allocation priority, the recent authorization
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
8 Jan 24
2 Strategy & Business Update J.P.Morgan Healthcare Conference 2024 Co - Founder, Board Co - Chair, President & Chief Executive Officer
6:30am
Scientific Officer
11 Relentless Innovation After 35 years, Regeneron is still pushing the boundaries of science and technology 2023 was another year … and Engineering Fair Environmental sustainability Pipeline innovation Access to medicine and fair pricing Patient advocacy Our mission: Use the power
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 Nov 23
Regeneron Reports Third Quarter 2023 Financial and Operating Results
7:10am
continued to deliver on our capital allocation priorities, primarily investing in internal and external innovation coupled with opportunistic share
PX14A6G
r7pbv7n8bdn5bqlc8
18 May 23
Letter to shareholders
4:46pm
8-K
EX-99.1
my4rkl05a aws0b
4 May 23
Regeneron Reports First Quarter 2023 Financial and Operating Results
7:11am
DEFA14A
e5nnhos8dl91q 3gkq1
21 Apr 22
Additional proxy soliciting materials
4:21pm
8-K
EX-99.1
42d 3dan5e0a
10 Jan 22
Results of Operations and Financial Condition
6:02am
DEFA14A
ylcgw v1uskril
23 Apr 21
Additional proxy soliciting materials
4:21pm